|
|
||||||||
Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
90% of the T cells, leaving a stable number of memory T cells. These memory cells are then maintained for extended periods of time and are able to respond much more quickly and to a greater magnitude than naive cells when challenged with the same Ag (1, 2, 3, 4).
The characterization of memory CD8+ T cell development has recently become an active area of investigation. Several reports have shown that, following initial activation of a CD8+ T cell response, a small percentage of the primary effector cell population up-regulates cell surface IL-7R (CD127) expression (5, 6). The IL-7R+ cells can be detected within 7 days of immunization, and it is this T cell population that is believed to give rise to memory cells. The IL-7R+ memory cell population can be further subdivided based on expression of other cell surface markers, such as the lymph node homing receptor CD62L (L-selectin) (5, 7). Central memory T cells (TCM), which express CD62L, reside preferentially in lymphoid organs, lack immediate effector functions, and are characterized by vigorous homeostatic and Ag-driven proliferation. Conversely, low-level expression of CD62L by peripheral effector memory T cells (TEM) promotes their preferential migration to nonlymphoid tissues. TEM cells proliferate poorly but are able to mediate immediate effector functions, such as IFN-
secretion and lysis of infected cells, upon re-encountering Ag in the peripheral tissues (8).
Both CD4+ and CD8+ T cells have been investigated for their protective role in immunity to the intracellular bacterial pathogen Chlamydia trachomatis. Mice lacking a CD4+ T cell response, as a result of mutations in either CD4 or MHC class II, were found to be considerably more susceptible to C. trachomatis infection than mice carrying a mutation in
2-microglobulin (which lack MHC class I and are therefore impaired in CD8+ T cell responses), suggesting a more dominant role for CD4+ T cells (9). Others have compared the role of CD4+ and CD8+ cells using spleen cells isolated from convalescent animals (10). Abs were used in vitro to deplete either the CD4+ or CD8+ T cells and then the resulting CD8+- or CD4+-enriched spleen cell populations were returned i.v. to infected mice. In these experiments, only the CD4+ cells were able to reduce the time course of infection. These experiments and others suggest that CD4+ T cells may be the main effectors of both primary and secondary immunity following natural infection (11).
The limited contribution of CD8+ T cells to clearance was unexpected given what we know about the biology of Chlamydia infection. C. trachomatis is a vacuolar pathogen that primarily infects genital tract epithelial cells. Unlike professional APCs, such as macrophages and dendritic cells, epithelial cells are unable to present pathogen-derived Ags in the context of MHC class II to CD4+ T cells. Therefore, CD8+ T cell surveillance should be the primary mechanism for recognition of Chlamydia-infected epithelial cells. In fact, CD8+ T cells have been shown to recognize Chlamydia-encoded Ags during C. trachomatis infection (12, 13, 14). We also have successfully protected mice against C. trachomatis infection by immunizing with recombinant vaccinia virus expressing these Chlamydia-specific CD8+ T cell Ags and by adoptively transferring cultured Chlamydia-specific CD8+ T cell lines into naive mice (12, 15). These results suggest that CD8+ T cells are capable of controlling Chlamydia growth yet fail to act during natural infection.
Because we expected that CD8+ T cells should be playing a more important role in controlling C. trachomatis infection, we decided to characterize the development of Chlamydia-specific CD8+ T cell responses. In this study, we report that the T cell response to Chlamydia Ags does not follow the kinetics observed using model pathogens such as L. monocytogenes and LCMV. Instead, C. trachomatis infection appears to alter the development of memory CD8+ T cells and, as a result, is able to suppress the recall response upon subsequent infection.
| Materials and Methods |
|---|
|
|
|---|
Female C57BL/6 (H-2b), CByB6F1 (H-2b/d), and B6.129P2-IL10tm1Cgn (IL10 knockout (KO)) mice were obtained from The Jackson Laboratory and used at 712 wk of age. Elementary bodies (EBs) of C. trachomatis serovar L2 434/Bu were propagated within and titered on McCoy cell monolayers, as previously described (12). EBs were diluted in sucrose-phosphate-glutamate buffer before immunization. Mice were infected i.v. with 107 inclusion-forming units (IFU) in 200 µl of buffer unless otherwise noted. We generated UV-inactivated C. trachomatis organisms by subjecting EBs to 10 min of UV irradiation. Construction of the recombinant vaccinia virus expressing the Chlamydia CrpA protein is described elsewhere (12). Virus preparations were treated with an equal volume of 0.25 mg/ml trypsin for 30 min at 37°C and diluted in PBS (106 PFU/200 µl) before immunization of mice. Listeria monocytogenes strain JJL-OVA (16) were grown to stationary phase in brain-heart infusion broth, aliquoted, titered, and stored at 80°C. Before immunization, bacteria were thawed on ice, grown to early exponential phase in brain-heart infusion broth, and diluted in PBS. Mice were infected i.v. with
103 CFU of Listeria in 200 µl of PBS.
ELISPOT analysis
ELISPOT analysis of CD8+ T cell responses following immunization with C. trachomatis, L. monocytogenes, or rVacCrpA was performed as described previously (12). The length of time postimmunization necessary to reach the peak of the CD8+ T cell response and the peptides used to stimulate the T cells varied depending on the immunogen. For animals infected with Chlamydia, spleen cells were harvested 6 days postimmunization and stimulated on CrpA6371-coated EL4 thymoma (H-2b) cells. For those infected with VacCrpA, spleen cells were harvested 7 days postimmunization and stimulated on CrpA6371-coated EL4 cells. Spleens from Listeria (JJL-OVA)-infected mice were harvested 7 days postimmunization and stimulated on EL4 cells coated with synthetic OVA257264 peptide. Peptides were purchased from Bio-Synthesis. The results are reported as the total number of spleen cells that secrete IFN-
in response to the appropriate peptide.
Phenotypic characterization of memory cell populations using flow cytometry
The Db/ASFVNPIYL (CrpA6371) MHC tetramer (allophycocyanin-conjugated) was generated at the National Institutes of Health Tetramer Facility (Bethesda, MD). Splenocytes were harvested from infected mice on the indicated days p.i. RBC were lysed, and the spleen cell suspension was enriched for CD3+ T cells using mouse T cell enrichment columns (R&D Systems). The resulting T cell populations were stained with the MHC tetramer as well as Abs against surface markers IL-7R (CD127) and CD62L (BD Pharmingen) and then sorted on a FACSCalibur flow cytometer (BD Biosciences).
Doxycycline treatment of mice
C57BL/6 mice were infected i.v. with 107 IFU of C. trachomatis as described above. Half of the mice received daily i.p. injections of doxycycline on days 721 p.i. The course of treatment was based on experiments conducted by Caldwell and colleagues (17). Each mouse received 100 µl of 3 mg/ml doxycycline hyclate (30 g per mouse at 10 mg/kg; Sigma-Aldrich). Following antibiotic treatment, mice were allowed to rest for 7 days to allow for degradation of residual doxycycline before challenging both the treated and untreated mice with C. trachomatis on day 28. The number of CrpA6371-specific CD8+ T cells was measured 5 days later using ELISPOT analysis.
| Results |
|---|
|
|
|---|
C. trachomatis infection has been shown to stimulate a robust CrpA-specific T cell response in naive mice with
4% of the splenic CD8+ T cells specific for CrpA6371 at the peak of the response (Ref. 12 and Fig. 1A). The number of CrpA-specific T cells then declines
10-fold, leaving a population of memory cells. To test the magnitude and kinetics of a T cell response to secondary Chlamydia infection, immune mice were challenged with C. trachomatis on day 28 postimmunization. The magnitude of the CrpA6371-specific secondary response was found to be significantly smaller than that of the primary response (Fig. 1A). In addition, the recall response to Chlamydia did not peak much earlier than it did during the primary response (day 5 vs day 6 postimmunization). These observations were in contrast to what has been shown for other pathogen-specific responses where recall is significantly enhanced, compared with the primary response. The diminished recall response also was seen with a second Chlamydia Ag, Cap1, suggesting that this is a general phenomenon of Chlamydia-specific T cell responses (data not shown).
|
, that are capable of suppressing the proliferation of CrpA-specific memory T cells. To test whether the secretion of IL-10 by Treg is responsible for the diminished secondary response to Chlamydia infection, we compared the CrpA-specific T cell response in wild-type C57BL/6 mice to the recall response in IL-10 KO mice (Fig. 1B). If IL-10-mediated suppression is involved, we would expect to see increased expansion of the CrpA-specific memory cells following challenge of the KO animals. However, the absence of IL-10 had no effect on the magnitude of the secondary response. Although we have not yet tested the role of TGF
in this process, the results in the IL-10 KO mice suggest that regulatory T cells are not responsible for the suppression of the secondary T cell responses.
We next sought to exclude the possibility that the reduced magnitude of the secondary response was simply a result of efficient clearance of infected cells before significant numbers of the memory T cells had an opportunity to respond. It has been shown that the magnitude of the primary response dictates the level of resting memory cells in immune mice, with a higher primary response leading to a greater number of memory cells (16). These memory cells respond to a secondary infection by proliferating and lysing infected cells. If the bacterial load is too low (or the number of memory cells is too high), the bacteria will be cleared before all the memory cells are reactivated, thus diminishing the apparent magnitude of the secondary response. To test whether the recall response could be enhanced by decreasing the number of CrpA-specific memory cells, we immunized naive mice with decreasing doses of C. trachomatis. The number of CrpA6371-specific T cells was measured at the peak of the primary response on day 6 p.i. using ELISPOT analysis (Fig. 1C,
). As expected, the number of CrpA-specific T cells decreased as the immunizing dose was reduced. We then challenged the groups of mice that had been immunized with the decreasing doses of organisms with 107 IFU of C. trachomatis and measured the number of CrpA-specific T cells at the peak of the secondary response (Fig. 1C,
). Mice that had been immunized with 105 IFU of C. trachomatis showed a lower recall response to CrpA6371 than mice that had received higher doses. Because reducing the number of memory cells did not enhance the subsequent recall response, we concluded that the suppression of the recall response results from diminished reactivity of the memory T cells, and not from efficient clearing of Ag.
Chlamydia-primed CD8+ T cells are limited in their capacity to develop into memory cells
The apparent defect in memory cell function led us to test whether C. trachomatis infection alters the development of memory cells specific for Chlamydia Ags. We measured the activation of memory T cells specific for CrpA6371 following immunization with C. trachomatis and compared it to the level of activation of the same population of naive CrpA-specific T cells observed following infection with a recombinant vaccinia virus expressing CrpA (VacCrpA) (12). Splenocytes were harvested from mice infected with either C. trachomatis or VacCrpA and stained with Db/CrpA6371 MHC tetramer and Abs against IL-7R and CD62L. On day 14 p.i., Chlamydia-immunized mice possessed a significantly lower percentage of CrpA-specific IL-7R+ memory cells than VacCrpA-immunized mice (Fig. 2A). This reduction in memory cell activation was most pronounced in the CD62Llow subpopulation, suggesting that it is the development of Chlamydia-specific effector memory T (TEM) cells that is inhibited during Chlamydia infection.
|
It has recently been shown that infections with persistent pathogens, such as HIV and certain strains of LCMV, lead to a decrease in the number of IL-7R+ memory cells and a subsequent loss of memory cell function (18, 19, 20). Interestingly, there is evidence that Chlamydia may also persist in vivo (21, 22) suggesting the possibility that the reduced activation of Chlamydia-specific TEM cells and subsequent failure of immune mice to mount a robust recall response may result from continuous low level T cell stimulation by persistent Chlamydia Ag. To test whether the elimination of organisms that may be persisting below detectable levels would improve the ability of Chlamydia-specific memory cells to respond to antigenic challenge we treated mice with the antibiotic doxycycline before challenge. Treatment of mice with doxycycline within the first 3 days of infection has been shown to alter development of primary CD4+ T cell responses by reducing the levels of available Ag (17). To ensure adequate priming of naive Chlamydia-specific CD8+ T cells, we waited 7 days after we infected mice with C. trachomatis before initiating antibiotic treatment. We then treated the mice daily with doxycycline from days 721 p.i.. Animals were removed from antibiotic treatment for 7 days and then both doxycycline-treated and untreated mice were re-infected with C. trachomatis. When we measured the number of CrpA6371-specific T cells we found that doxycycline treatment had no effect on the magnitude of the CrpA-specific secondary response (Fig. 2C), suggesting that reducing the number of persistent organisms using antibiotic treatment failed to improve the ability of Chlamydia-specific memory cells to respond to challenge.
C. trachomatis infection poorly reactivates memory cells primed by VacCrpA
The results described above suggested that there is a functional defect in Chlamydia-induced memory cells that prevents them from responding to an antigenic challenge. However, it is also possible that the memory cells are functionally normal but that C. trachomatis infection fails to activate them. To test whether CrpA-specific memory cells are capable of responding to antigenic stimulation, Chlamydia-immune mice were challenged with either C. trachomatis or VacCrpA (Fig. 3). Significantly more CrpA-specific T cells were observed when the Chlamydia-immune mice were challenged with VacCrpA than when they were challenged with C. trachomatis (p < 0.001). We also found that Chlamydia infection poorly reactivated CrpA-specific memory cells in VacCrpA-immunized mice (Fig. 3). We were unable to compare the secondary response following Chlamydia infection to the same response following challenge with VacCrpA because expansion of immunodominant vaccinia-specific T cells overwhelms the CrpA-specific response (Ref. 23 and our unpublished observations). Together, these data suggest that the Chlamydia-induced memory cells are capable of responding reasonably well to Ag but that C. trachomatis infection may not provide an optimal environment for stimulating Chlamydia-specific T cells.
|
To further test whether C. trachomatis infection can inhibit the development of CD8+ T cell responses, we tested whether the presence of Chlamydia could affect the activation of CD8+ T cells specific for Listeria monocytogenes. Listeria infection has been used extensively as a model system for studying T cell activation because the bacteria induce robust CD8+ T cell responses that are crucial for clearing the infection (1, 24). Groups of mice were immunized with LmOVA, a recombinant strain of Listeria expressing OVA, either alone or in combination with various doses of C. trachomatis. After 7 days, the number of T cells specific for the OVA257264 (SIINFEKL) peptide was measured using ELISPOT analysis (Fig. 4A). Coinfection with Chlamydia led to a dose-dependent decrease in the OVA257264-specific T cell response stimulated by LmOVA, suggesting that Chlamydia can inhibit the priming of heterologous CD8+ T cell responses. The inhibitory phenotype was dependent on coinfection with live Chlamydia because coinfection with UV-inactivated organisms failed to have a significant effect on T cell priming (data not shown).
|
We then asked whether Chlamydia infection could reduce the reactivation of OVA-specific memory T cells. The stimulation of memory cells differs from naive cells in that activation of memory cells does not require costimulation. They simply need to recognize peptide-MHC complexes to proliferate. C57BL/6 mice were infected with LmOVA alone or in combination with C. trachomatis. After 21 days, each group of mice was divided with half being challenged with LmOVA alone (Lm) while the other half was coinfected with LmOVA and Chlamydia (Lm/CT)(Fig. 4C). LmOVA alone stimulated a robust secondary response to the OVA257264 peptide when compared with the LmOVA alone primary response (Fig. 4C,
). Challenging the Lm mice with Lm/CT resulted in a significant reduction in the OVA-specific recall response suggesting that the presence of Chlamydia inhibits the expansion of the Listeria-specific memory cells. The Lm/CT-immune mice responded more robustly to a challenge with Lm than did the Lm-immune mice perhaps as a result of there being fewer memory cells present to compete for available Ag (16). Consistent with there being fewer memory cells in the Lm/CT-immune mice, Chlamydia infection was better able to suppress memory cell expansion in mice that had been immunized with Lm/CT than in the Lm-immune mice. Together, these results suggest that Chlamydia infection is able to alter the environment at the site of T cell activation to inhibit the expansion of both naive and memory Listeria-specific CD8+ T cells and it seems likely that a similar inhibitory mechanism could be acting on Chlamydia-specific T cells.
| Discussion |
|---|
|
|
|---|
Studies on the kinetics of CD8+ T cell responses to Chlamydia Ags show a relatively robust primary response to CrpA6371 (12). However, upon challenge with C. trachomatis the magnitude of the CrpA-specific recall response was found to be quite small compared with the primary response (Fig. 1). This reduced secondary response was quite surprising considering the large body of evidence showing that reactivation of memory T cells results in rapid proliferation with a 5- to 10-fold increase in magnitude relative to the primary response. Interestingly, most of these studies were done using pathogens, such as L. monocytogenes, that cause acute infections (1, 2, 3). However, it is now becoming clear that this model may not accurately reflect the response to persistent pathogens.
Several recent reports have examined persistent viral infections, such as HIV and LCMV, and found that the presence of persistent Ag leads to a decrease in the number of IL-7R+ cells (18, 19, 20). The evidence that Chlamydia persists in vivo (22, 25) led us to look at the expression of IL-7R on CrpA6371-specific T cells. We saw a significant decrease in IL-7R+ memory cells in Chlamydia-infected mice compared with mice that had been immunized with a recombinant vaccinia virus expressing the Chlamydia CrpA protein (Fig. 2). This suggested that Chlamydia infection was inhibiting the development of CD8+ memory T cells, which could as a result decrease the ability of Chlamydia-specific memory cells to respond to a secondary challenge. However, this reduced recall response most likely did not result from persistent Chlamydia organisms because treating the infected mice with the antibiotic doxycycline had no effect on the magnitude of the CrpA-specific secondary response (Fig. 2C).
We show that it is specifically the TEM population that is inhibited during Chlamydia infection, especially on day 14 p.i. (Fig. 2A). By day 35 p.i., it appeared that the memory population in Chlamydia-infected animals was skewed toward a TCM, rather than a TEM, phenotype. This result is interesting in light of recent work by Bachmann et al. (26) examining the relative roles of central vs effector memory T cells in mediating protection against viral infection. They found that the effectiveness of TCM and TEM cells in mediating antiviral protection depended on the site of viral replication and the relative contribution of cytokines vs perforin-mediated cell lysis. For example, vaccinia virus replicates predominantly in peripheral solid organs, such as ovaries, and the primary mechanism of protection is cytokine secretion, in particular the secretion of IFN-
and TNF-
. To effectively control vaccinia infection, Ag-specific CD8+ T cells had to be found in peripheral organs at the time of challenge and they had to secrete high levels of IFN-
(26). The ability to migrate into peripheral tissues and to rapidly secrete cytokines are hallmarks of TEM cells. Like vaccinia, Chlamydia infect peripheral tissues, namely the genital tract, and there is abundant evidence that IFN-
secretion, rather than perforin-mediated lysis, is essential for controlling a Chlamydia infection (27, 28, 29, 30). We would therefore predict that TEM cells would be playing an important role in conferring protection. Yet this is the population that is most significantly altered during Chlamydia infection suggesting that the bacteria may be inhibiting the development of the T cell population most likely to control a secondary infection.
How is Chlamydia able to alter the development of memory CD8+ T cells? We showed that the kinetics of memory cell development does not dictate whether Chlamydia-specific memory cells respond to challenge. We failed to improve recall by reducing the number of memory cells competing for Ag during a secondary challenge (Fig. 1C) or by waiting to challenge the mice until day 35 p.i. when a higher percentage of CrpA-specific cells express a memory phenotype (Fig. 2B). These data suggest that the memory cells that develop during Chlamydia infection are functionally defective and therefore unable to control bacterial growth.
Our results demonstrating that fewer Listeria-specific T cells are stimulated in the presence of Chlamydia infection suggest that inhibition is occurring at the time of initial T cell activation (Fig. 4). During the priming phase, many costimulatory signals are transmitted from APCs to naive CD8+ T cells. Some lead to the generation of effector T cells that are capable of clearing a primary infection, while other signals direct naive T cells to undergo memory cell differentiation (31). It is tempting to speculate that reduced costimulatory signals could explain our results. However, reduced costimulation could only inhibit the priming of Listeria-specific T cells if Listeria and Chlamydia are infecting the same APCs. It is difficult to imagine that Chlamydia significantly inhibits Listeria-specific priming in this manner because it is unlikely that a sufficient number of APCs are coinfected, particularly when the Chlamydia was introduced 224 h before the Listeria. In addition, C. trachomatis infection was shown to affect the reactivation of Ag-experienced memory cells, which do not require costimulatory signaling to induce proliferation (Fig. 4C). Therefore the reduced priming of Listeria-specific T cells suggests that Chlamydia infection alters the local environment in such a way as to at least partially inhibit the priming of naive CD8+ T cells.
Induction of regulatory T cells during infection has been shown in a number of systems to result in reduced memory responses (32, 33, 34). One possible explanation for the suppression of memory T cell responses in our system is the presence of Chlamydia-specific regulatory T cells. The induction of Chlamydia-primed Tregs might explain why Chlamydia coinfection has a greater impact on the reactivation of Listeria-specific T cells primed in the presence of C. trachomatis, but Chlamydia infection is also able to reduce the initial priming of Listeria-specific T cells in naive mice or mice that had been previously infected with LmOVA alone (Fig. 4). There is evidence that some pathogens, such as HSV, can activate natural Tregs and as a result regulate primary T cell responses (34). It is therefore possible that Chlamydia infection leads to diminished T cell responses through the activation of Treg. We have begun to address the role of Treg by examining whether IL-10 secretion contributes to suppression of the Chlamydia-specific T cell response. Infecting IL-10 KO mice failed to improve either the primary or secondary response against CrpA (Fig. 1B), suggesting that regulatory T cells are not necessary for this phenotype. However, IL-10 is not the only immunosuppressive cytokine implicated in Treg function. Studies are currently underway to determine whether TGF
is playing a role in this process.
It has long been appreciated that immunization with live Chlamydia provides minimal protection against subsequent challenge. Our data suggest that this limited protection during secondary infection may be due to the failure of CD8+ T cells to respond adequately. Our goal is to understand the mechanism behind this apparent suppression. Ultimately, this knowledge could be used to develop more effective immunization protocols capable of overcoming this suppression.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by National Institute of Allergy and Infectious Diseases Grants AI039558, AI055900, and AI055962. ![]()
2 Address correspondence and reprint requests to Dr. Michael N. Starnbach, Department of Microbiology and Molecular Genetics, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115. E-mail address: starnbach{at}hms.harvard.edu ![]()
3 Abbreviations used in this paper: LCMV, lymphocytic choriomeningitis virus; p.i., postinfection; TEM, effector memory T cell; TCM, central memory T cell; EB, elementary body; IFU, inclusion-forming unit; KO, knockout; Treg, regulatory T cell. ![]()
Received for publication January 15, 2006. Accepted for publication June 27, 2006.
| References |
|---|
|
|
|---|
interferon in controlling murine chlamydial genital tract infection. Infect. Immun. 67: 5518-5521.
interferon in host defense against Chlamydia trachomatis infections. Infect. Immun. 57: 152-157.
interferon production by cytotoxic T lymphocytes is required for resolution of Chlamydia trachomatis infection. Infect. Immun. 66: 5457-5461. This article has been cited by other articles:
![]() |
C. Hermann Review: Variability of host pathogen interaction Innate Immunity, August 1, 2007; 13(4): 199 - 218. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |